drugset / Trial / NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
Timeline
- Start
- 2025-12-12
- Primary completion
- 2029-10
- Completion
- 2033-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vepugratinib | Unknown | — | Oral |
| Background | Enfortumab Vedotin | Other / unclassified | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |